2028 Marketing Regulations Treatment 
Drug Discovery World
JULY 25, 2024
According to data analysts Precedence Research, the global biotechnology market was estimated at $1.38 Following a subdued 2022 and 2023 for biotech investment, there is optimism that the market is heading to recovery in 2024. In 2021, the country had the seventh largest share of the global biotech market 2.
Drug Discovery World
SEPTEMBER 26, 2022
According to MarketWatch, the drug repurposing sector was thought to be worth $25,280 in 2021 and is expected to grow to $30,620 million by 2028 with a CAGR of 2.8%. Perhaps the biggest benefit drug repurposing brings is its potential to get treatments to patients faster than traditional means of drug discovery. Diving into data .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 28, 2022
With the advent of natural language processing, algorithms can now also contextualise these data and, combined with trend analysis, can guide researchers towards areas more likely to show promising treatments. . According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2
The Premier Consulting Blog
NOVEMBER 20, 2023
The FDA is proposing a change to its regulations to explicitly classify In Vitro Diagnostics (IVDs) as devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act), irrespective of the manufacturer being a laboratory that previously conducted business and was certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
Agency IQ
AUGUST 16, 2024
By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Sponsors should plan to justify the inclusion of a psychotherapy component.”
Agency IQ
JUNE 28, 2024
New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. Sections 5 – 9 are labeled as Part A and cover clinical evaluation considerations.
Drug Discovery World
AUGUST 10, 2022
By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. But decades of research led to improvements in cancer therapy, centred around the idea that one’s immune system could aid in treatment.
Expert insights. Personalized for you.
130 
Let's personalize your content